Zai Lab Limited
NASDAQ:ZLABBiotechnology
+$0.61 today
- Market cap
- $2.49B
- Beta
- 0.78
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.16
Volume 1.04M
Average 0.87M
ZLAB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Zai Lab LimitedNASDAQ: ZLAB
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $50.83M (cash outflow) rose 24.8% year over year, ahead of the -11.4% change in trailing-twelve-month net income. Sequentially, it fell 0.4% from the prior quarter. Over 3 fiscal years it compounded at -26.6% a year.
Context
- Net income amounted to 38.1% of revenue in FY2025, down 26.3 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$213.54M (+21.6%) for the fiscal year ending Dec 2026, a step up from the -31.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$50.83M-0.4% QoQ
- Last fiscal yearDec 2025
- -$175.54M-31.7% YoY
- LTMJun 2026
- -$188.21M-11.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +24.8% | +84.9% | +60.1 pp |
| 1 year | -31.7% | +21.6% | +53.4 pp |
| 3-year CAGR | -26.6% | -5.9% | +20.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (175.54M) USD
- Year-over-year change
- +31.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (175.54M) | +31.7% |
| FY2024 | 2024-12-31 | (257.1M) | +23.2% |
| FY2023 | 2023-12-31 | (334.62M) | +24.5% |
| FY2022 | 2022-12-31 | (443.29M) | +37.1% |
| FY2021 | 2021-12-31 | (704.47M) | — |
Net Income vs competitors
How ZLAB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.4% is the lowest of 3, against a peer median of +712.6%.
- Net income amounts to 41.9% of revenue for ZLAB, versus a peer median of 221.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.24B CNY | +212.7% | +11.7% | 221.3% |
| LTM Jun 2025 | $466.88M USD | +1212.4% | — | 77.5% | |
| LTM Jun 2026 | $188.21M USD | -11.4% | -26.6% | 41.9% | |
| LTM Jun 2024 | $54.07M USD | — | -15.4% | 833.1% | |
| Peer median (excluding ZLAB) | — | +712.6% | -1.8% | 221.3% | |
Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (704.47M) | (443.29M) | (334.62M) | (257.1M) | (175.54M) |
| Depreciation & Amortization | 6.49M | 8.23M | 9.03M | 11.86M | 15.01M |
| Deferred Income Tax | 17.08M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.71M | 61.3M | 79.63M | 70.65M | 65.6M |
| Change in Working Capital | 23.11M | (66.25M) | 39.61M | (68.39M) | (54.71M) |
| Accounts Receivables | (42.32M) | 25.14M | (17.69M) | (26.58M) | (29.98M) |
| Inventory | (7.17M) | (15.38M) | (14.91M) | 3.9M | (47.03M) |
| Accounts Payables | 63.52M | (53.77M) | 36.8M | (2.21M) | 19.93M |
| Other Working Capital | 9.08M | (22.23M) | 35.4M | (43.5M) | 2.38M |
| Other Non-Cash Items | 67.85M | 72.36M | 8.17M | 28.12M | (1.15M) |
| Operating Cash Flow | (549.23M) | (367.64M) | (198.18M) | (214.87M) | (150.79M) |
| Capital Expenditures | (18.95M) | (24.98M) | (8.49M) | (61.52M) | (13.42M) |
| Acquisitions (Net) | (30M) | 0 | 0 | 29K | 0 |
| Purchases of Investments | (445M) | (260.27M) | (134M) | (330M) | (10M) |
| Sales of Investments | 743.9M | 705.27M | 117.7M | 16.3M | 331.2M |
| Other Investing Activities | 3K | (399K) | 12.74M | (55.86M) | (5.24M) |
| Investing Cash Flow | 249.96M | 420.02M | (10.78M) | (375.19M) | 307.87M |
| Debt Repayment | 0 | 0 | 0 | 131.32M | 67.94M |
| Common Stock Issued | 818.88M | 0 | 0 | 217.35M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.33M | (1.73M) | (6.43M) | 1.22M | (9.27M) |
| Financing Cash Flow | 820.2M | (1.73M) | (6.43M) | 349.89M | 72.35M |
| Effect of Forex Changes | 1.12M | (6.27M) | (2.62M) | (310K) | 478K |
| Net Change in Cash | 522.04M | 44.37M | (218.01M) | (240.48M) | 229.91M |
| Free Cash Flow | (568.18M) | (392.63M) | (206.67M) | (276.39M) | (164.21M) |
Zai Lab Limited
NASDAQ:ZLAB
Intrinsic Alpha fair value
Locked
Current Price
$22.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.